Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-4595 for Injection Receives Drug Clinical Trial Approval Notice

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Suzhou Suncadia Biopharmaceuticals Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-4595 for Injection, and will soon initiate clinical trials. SHR-4595 for Injection is a therapeutic biological product independently developed by the company, which can specifically bind to antigens on the surface of tumor cells and kill tumor cells, and is intended for the treatment of advanced malignant solid tumors. Upon review, one drug targeting the same target as this product has been approved for marketing both domestically and internationally. As of now, the cumulative R&D investment in SHR-4595 for Injection-related projects is approximately 16.4 million yuan (unaudited).